GSK Secures High Blood Pressure Drug in $950 Million Deal (1)

GSK Plc agreed to buy 35Pharma Inc., a biotech with an early-stage drug for pulmonary hypertension, as the UK pharma giant boosts its pipeline of promising experimental therapies.

GSK will buy the closely held Canadian firm for $950 million in cash, it said in a statement Wednesday.

GSK hopes the drug — called HS235 — will be effective in treating a disease characterized by high blood pressure in the lungs that can cause heart failure. The deal also boosts GSK’s small pipeline of therapies for diseases that also affect the heart and metabolic systems. The company already has a range ...